The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Roitman A.P.

Fedorova T.A.

Nauchnyĭ tsentr akusherstva, ginekologii i perinatologii im. akad. V.I. Kulakova, Moskva

Ivanova E.A.

Pirogov Russian National Research Medical University, Moscow, Russia

Bugrov A.V.

Department of clinical laboratory diagnostics, Russian medical Academy of postgraduate education of the Russian Federation, Moscow, Russia

Dolgov V.V.

GBOU VPO "Rostovskiĭ gosudarstvennyĭ meditsinskiĭ universitet"

The role of metabolism disorders, inflammation, myocardial injury in development chronic heart failure in metabolic syndrome patients

Authors:

Roitman A.P., Fedorova T.A., Ivanova E.A., Bugrov A.V., Dolgov V.V.

More about the authors

Journal: Laboratory Service. 2018;7(4): 5‑10

Read: 12531 times


To cite this article:

Roitman AP, Fedorova TA, Ivanova EA, Bugrov AV, Dolgov VV. The role of metabolism disorders, inflammation, myocardial injury in development chronic heart failure in metabolic syndrome patients. Laboratory Service. 2018;7(4):5‑10. (In Russ.)
https://doi.org/10.17116/labs201870415

Recommended articles:
New aspe­cts of psoriasis pathogenesis: meta­bolomic profiling in dermatology. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(5):526-531
The role of immuno-inflammatory factors in the deve­lopment of nega­tive symptoms in schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):42-48
Meta­bolic syndrome and anti­psychotic therapy of schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):165-170

References:

  1. Won H, Kang S-M, Shin MJ, et al. Plasma Adiponectin Concentration and Its Association with Metabolic Syndrome in Patients with Heart Failure. Yonsei Medical Journal. 2012;53(1):91-98. https://doi.org/10.3349/ymj.2012.53.1.91
  2. Belenkov YuN, Mareev VYu. Pervie rezultat nacionalnogo epidemiologichescogo issledovaniya bolnych HSN v realnoy practice. EPOHA-O-HSN. Serdechnaya nedostatochnost. 2003;4(3). (In Russ.)
  3. Drapkina OM, Ivashkin BT, Korneeva ON. Klinicheskie varianty metabolicheskogo sindroma. M.:MIA, 2012. (In Russ.)
  4. Andreassen AK, Nordøy I, Simonsen S, et al. Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation. Am J Cardiol. 1998;81(5):604-608. https://doi.org/10.1016/s0002-9149(97)00972-7
  5. Petersen JW, Felker M. Inflammatory Biomarkers in Heart Failure. Congestive Heart Failure. 2006;12(6):324-328. https://doi.org/10.1111/j.1527-5299.2006.05595.x
  6. Kocheruga TN, Makarevich PI, Ovchinnikov AG., Zhigunova LV. Circulating factors associatedwith metabolic disorders in patients with post-infarction heart failure. Serdechnaya nedostatochnost. 2013;14(78):191-199. (In Russ.)
  7. Coffman E, Richmond-Bryant J. Multiple biomaker models for improved risk estimation of specific cardiovascular diseases related to metabolic syndrome: a cross-sectional study. Population Health Metrics. 2015;13(7):1-15. https://doi.org/10.1186/s12963-015-0041-5
  8. Bozkurt B, SB, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-a promote progressive left ventricular dysfunction and remodeling in rats // Circulation. 1998;97:1382-1391. https://doi.org/10.1161/01.cir.97.14.1382
  9. Levine B, Kalman J, Mayer I, et al. Elevated circulating level of tumor necrosis factor in severe chronic heart failure. New England Journal of Medicine. 1990;323(4):236-241. https://doi.org/10.1056/nejm199007263230405
  10. Anker S, Swan JW, Volterrani M, et al. The influence of muscle mass strength and fatiguability and blood flow on exercise capacity in cachectic and non cachectic patients with chronic HF. European Heart Journal. 1997;18(2):259-269. https://doi.org/10.1093/oxfordjournals.eurheartj.a015229
  11. Secchierro P, Corallini F, Ceconi C, et al. Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. PLOS One. 2009;4(2):1-6. https://doi.org/10.1371/journal.pone.0004442
  12. Osmancik P, Herman D, Stros P, et al. Changes and prognostic impact of apoptotic and inflammatory cytokines in patients treated with cardiac resynchronization therapy. // Cardiology. 2013;124(3):190-8. Epub 2013 Mar 12. https://doi.org/10.1159/000346621
  13. Krikunova OV, Vasyuk YuA, Viskov RV, et al. Significance of troponin tests for differential diagnosis and prediction in heart failure. Serdechnaya nedostatochnost. 2015;16(4):254-260. (In Russ.) https://doi.org/10.18087/rhfj.2015.4.2122
  14. Nagarajan V, Hernadez AV, Tang WH, Prognostic value of cardiac troponin in chronic stable heart failure: a systematic rewiew. Heart. 2012;98(24):1778-1786. https://doi.org/10.1136/heartjnl-2012-301779
  15. Rubin J, Matsushita K, Ballantyne CM, et al. Chronic hyperglycemia and subclinical myocardial injury. // J Am Coll Cardiol. 2012; 31;59(5):484-9. https://doi.org/10.1016/j.jacc.2011.10.875
  16. Fukuta H, Ohte N, Wakami K, et al. Relation of Plasma Levels of Adiponectin to Left Ventricular Diastolic Dysfunction in Patients Undergoing Cardiac Catheterization for Coronary Artery Disease. The American Journal of Cardiology. 2011;108(8):1081-1085. https://doi.org/10.1016/j.amjcard.2011.06.005
  17. Fujioka D, Kawabata K, Saito Y, et al. Role of adiponectin receptors in endothelin-induced cellular hypertrophy in cultured cardiomyocytes and their expression in infarcted heart. American Journal of Physiology-Heart and Circulatory Physiology. 2006;290(6):H2409-H2416. https://doi.org/10.1152/ajpheart.00987.2005
  18. Iwaoka M, Obata J, Abe M et al. Association of Low Serum Levels of Apolipoprotein A-I With Adverse Outcomes in Patients With Nonischemic Heart Failure. Journal of Cardiac Failure. 2007;13(4):247-253. https://doi.org/10.1016/j.cardfail.2007.01.007
  19. Giamouzis G, Butler J. Relationship Between Heart Failure and Lipids: The Paradigm Continues to Evolve. Journal of Cardiac Failure. 2007;13(4):254-258. https://doi.org/10.1016/j.cardfail.2007.03.009
  20. Ingelsson E, Arnlov J, Sudstrom J et al. Novel Metabolic Risk Factors for Heart Failure. Journal of the American College of Car足di足o足lo足gy. 2005;46(11):2054-2016. https://doi.org/10.1016/j.jacc.2005.07.059
  21. Borja MS, Hammerson B, Tang C, et al. Apolipoprotein A-I exchange is impaired in metabolic syndrome patients asymptomatic for diabetes and cardiovascular disease. PLoS One. 2017 Aug 2;12(8):e0182217. eCollection 2017. https://doi.org/10.1371/journal.pone.0182217
  22. Lim Y, Yoo S, Lee SA, et al. Apolipoprotein B is related to Me足ta足bo足lic Syndrome independently of Low Density Lipoprotein Cho足lesterol in patients type 2 Diabetes. Endicrinology and metabolism. 2015;30(2):208-215. https://doi.org/10.3803/enm.2015.30.2.208
  23. Lind L, Vessby B, Sundstrom J. The Apolipoprotein B/AI ratio and the Metabolic Syndrome independently predict risk for myocardial infarction in middle-aged men. Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26(2):406-410. https://doi.org/10.1161/01.atv.0000197827.12431.d0

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.